实体器官移植受者的药物基因组学与个体化药物治疗
本文为叙述性综述,讨论药物基因组学与治疗药物监测在实体器官移植受者免疫抑制剂及常用药物中的创新与床旁应用,关注药物制剂互换、免疫系统活性生物检测,并以案例形式展示药物-药物、药物-基因及药物-药物-基因相互作用的系统化处理。
要点
- 移植受者依赖治疗窗窄的免疫抑制剂,且因合并症和用药复杂易发生药物不良事件。
- 综述强调药物基因组学与治疗药物监测在免疫抑制及移植常用药物中的床旁应用。
- 需关注急性诊疗中药物制剂互换问题,并以案例整合药物相互作用与基因检测。
核心结论
- 药物基因组学与治疗药物监测可用于优化实体器官移植受者的免疫抑制及常用药物个体化治疗。
研究设计与样本
- 叙述性综述,讨论药物基因组学与治疗药物监测在实体器官移植受者中的应用。
主要发现
- 移植受者因合并症负担和用药方案复杂而易发生药物不良事件。
- 急性诊疗中常需药物制剂互换,需特别关注制剂因素。
- 可量化免疫系统活性的生物检测具有实际应用价值。
临床怎么用
- 以案例为基础,整合药物基因组学、治疗药物监测、药代动力学和药效学原则处理药物-药物、药物-基因及药物-药物-基因相互作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Solid organ transplant recipients are reliant on immunosuppressive drugs, which have a narrow therapeutic index, and are concurrently vulnerable to adverse drug events due to comorbidity burden and the complexity of their medication regimens. Urgent management of post-transplant complications often falls to the generalist clinician or critical care specialist. The purpose of this narrative review is to discuss innovations and bedside applications of pharmacogenomics and therapeutic drug monitoring applied to immunosuppression and agents frequently encountered in transplant recipients. Medication formulations will be given specific attention, as interchange is frequently required in the acute care setting. Bioassays quantifying immune system activity will be described with practical applications. A structured approach to addressing drug-drug, drug-gene, and drug-drug-gene interactions will be modeled using a case-based approach synthesizing pharmacogenomics, therapeutic drug monitoring, pharmacokinetics, and pharmacodynamic principles.
引用
- Lemke A, Wright J, May H, et al. Pharmacogenomics and beyond! Customized pharmacotherapy for solid organ transplant recipients. Pharmacotherapy. 2023. PMID: 36999337. doi:10.1002/phar.2798
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。